Posts Tagged ‘epigenética’

Categories

Posted in:

Tuesday May 22nd, 2018

IDIBAPS researchers decipher how leukaemia’s genome works

A team of researchers from IDIBAPS show for the first time the complete epigenome of chronic lymphocytic leukaemia, the most common type of leukaemia. The study, published in Nature Medicine, provides a high-resolution map of the functions of the genome, which steps forward into cancer molecular research. The comparison of the map for this type of leukaemia with the map of healthy cells shows hundreds of regions that change their functionality in leukaemia which help to understand the illness better and represent potential targets for the development and application of new therapies. Read the rest of this entry »

Comments Closed
Thursday November 17th, 2016

Clinic-IDIBAPS researchers identify that the epigenetic history of lymphoma predicts its clinical course

A study published in the journal Cancer Cell  deciphers for the first time the epigenome of mantle cell lymphoma, an aggressive type of cancer derived from B lymphocytes, the cells of the immune system responsible for producing antibodies. The research reveals in detail the epigenetic history of lymphoma. On the one hand, it identifies the cell of origin and, on the other, it reveals that the more the epigenome of tumor cells evolves, the more aggressive the patient’s clinical course is. In addition, researchers discover that three-dimensional DNA conformation changes in lymphomas and leads to the activation of cancer genes. Dr. Iñaki Martín-Subero has coordinated the study. He is researcher at the University of Barcelona and at the Molecular Mechanisms of Lymphoid Neoplasms IDIBAPS research group, led by Dr. Elías Campo.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday September 27th, 2016

IDIBAPS researchers identify a new therapeutic target for liver cancer

IDIBAPS researchers have identified the first epi-driver in liver cancer, a type of epigenetic alteration in the IGF2 gene that causes tumors to grow. In the study, published in the Gastroenterology journal, they have found that this alteration occurs in 15% of tumors and that a monoclonal antibody can effectively block it and slow tumor progression in animal models. Dr. Josep M. Llovet, ICREA Professor, Head of the Translational research in hepatic oncology IDIBAPS group and Director of the Mount Sinai Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York), has coordinated this study. The first authors of the article are Iris Martínez-Quetglas and Roser Pinyol, researchers at the same team.

Read the rest of this entry »

Comments Closed